Hydrogenology
Hydrogenology editorial study record

The effect of a low dose hydrogen-oxygen mixture inhalation in midlife/older adults with hypertension: A randomized, placebo-controlled trial

Liu B et al. · Front Pharmacol. 2022;13:1025487.

HumanInhaled H₂Published 2022
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Randomized placebo-controlled parallel trial

Research topic

Cardiovascular and circulatory health

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adults aged 50–70 years with hypertension

Sample

60 randomized; 56 completed: H₂–O₂ n=29, air n=27

Duration

4 hours/day for 2 weeks

Intervention

Hydrogen–oxygen mixture inhaled 4 hours/day

Hydrogen form

Brown’s gas / oxyhydrogen: 66% H₂ and 33% O₂ were co-delivered.

H₂ specification

Total mixed-gas flow 30–60 mL/min. After dilution with room air, inspired H₂ was reported as approximately 0.2–0.4%.

H₂ flow

19.8–39.6 mL/min H₂, calculated by Hydrogenology as 66% of the reported 30–60 mL/min mixed-gas flow.

O₂ delivered with H₂

9.9–19.8 mL/min O₂, calculated as 33% of the reported mixed-gas flow.

Comparator

Air inhaled from a matched placebo device

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Four-limb blood pressure, 24-hour ambulatory blood pressure and plasma hormones

Reported result

Arm systolic pressure and nighttime ambulatory diastolic pressure decreased within the H₂–O₂ group. Several conclusions rely on within-group comparisons; the record does not treat these as proof of broad between-group superiority.

Results-extraction completeness

Gas composition, flow, main results, funding and conflict statement checked in the free full text; component flows are transparent calculations from the reported total.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Short 56-person completion sample, several within-group analyses and subgroup comparisons. Public Chinese grants funded the study; the device company was acknowledged, and authors declared no commercial or financial conflict.

Applies directly to

Adults aged 50–70 with hypertension under this two-week protocol.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 36278221 · DOI: 10.3389/fphar.2022.1025487

Publisher access

Open-access article.

Extraction basis

Free full text on PMC and Frontiers; identifiers cross-checked in PubMed.

Record revision

2026-08-10